| Previous Close | 72.11 |
| Open | 72.08 |
| Bid | 72.54 x 100 |
| Ask | 72.71 x 100 |
| Day's Range | 72.08 - 72.96 |
| 52 Week Range | 63.76 - 82.10 |
| Volume | 4,456,259 |
| Avg. Volume | 8,772,639 |
| Market Cap | 94.82B |
| Beta | 1.08 |
| PE Ratio (TTM) | 7.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.88%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Barrons.com•2 hours ago
Gilead: Where's the Urgency?
Gilead Sciences (GILD) has gained 13% during the past three months as investors have started to bet that the beaten-down biotech stock has finally found a bottom. The iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.1% to $303.67.
- Zacks•3 days ago
Mylan Finalizes Settlement Agreement with DOJ for $465M
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
- Market Realist•3 days ago
Let’s Explore How Cost Leadership Provides Market Control
Firms with a structural cost advantage can either undercut competitors on price while earning similar margins, or they can charge market-level prices while earning relatively high margins.
